Evidence
Mol Cell Proteomics. 2024 Jan 19:100721. doi: 10.1016/j.mcpro.2024.100721. Online ahead of print.
ABSTRACT
Alzheimer’s disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques), intraneuronal inclusions of phosphorylated tau (tangles), as well as neuronal and synaptic degeneration, accompanied by tissue reactions to these processes (astrocytosis and microglial activation) that precede neuronal network disturbances in the symptomatic phase of the disease. A number of biomarkers for these brain tissue changes have been developed, mainly using immunoassays. In this review, we discuss how targeted mass spectrometry (TMS) can be used to validate and further characterize classes of biomarkers reflecting different AD pathologies, such as tau- and amyloid-beta pathologies, synaptic dysfunction, lysosomal dysregulation, and axonal damage, and the prospect of using TMS to measure these proteins in clinical research and diagnosis. TMS advantages and disadvantages in relation to immunoassays are discussed, and complementary aspects of the technologies are discussed.
PMID:38246483 | DOI:10.1016/j.mcpro.2024.100721
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Genomic stress and impaired DNA repair in Alzheimer disease
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
- Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer's disease mouse model, as revealed by spatial transcriptomics
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change
- Towards cascading genetic risk in Alzheimer's disease
- Personalized whole-brain neural mass models reveal combined Ab and tau hyperexcitable influences in Alzheimer's disease
- Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection
- Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease
- Proteomics Impact on Cell Biology to Resolve Cell Structure and Function
- Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease
- Proteomic analysis of P. gingivalis-Lipopolysaccharide induced neuroinflammation in SH-SY5Y and HMC3 cells
- Resiliency to Alzheimer's disease neuropathology can be distinguished from dementia using cortical astrogliosis imaging
- P2Y1 receptor in Alzheimer's disease
- Thermal evaporation as sample preparation for silver-assisted laser desorption/ionization mass spectrometry imaging of cholesterol in amyloid tissues
- Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy
- Extracellular ATP is a homeostatic messenger that mediates cell‒cell communication in physiological processes and psychiatric diseases
- Extracellular ATP is a homeostatic messenger that mediates cell‒cell communication in physiological processes and psychiatric diseases
- Regulated cell death and its role in Alzheimer's disease and amyotrophic lateral sclerosis
- Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis
- Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid
- Evaluation of altered cell-cell communication between glia and neurons in the hippocampus of 3xTg-AD mice at two time points
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- A new angle on transcranial magnetic stimulation coil orientation: A targeted narrative review
- The complexity of extracellular vesicles: Bridging the gap between cellular communication and neuropathology
- G-protein coupled estrogen receptor 1, amyloid-β, and tau tangles in older adults
- Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer's disease
- The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes
- Long-Term High-Fat Diet Consumption Aggravates β-Amyloid Deposition and Tau Pathology Accompanied by Microglial Activation in an Alzheimer's Disease Model
- Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3
- Altering plasma lipids and liver enzyme activities via hippocampal injections of hen Lysozyme amyloid aggregates in an Alzheimer's disease mouse model: Insights into the therapeutic role of Bis (Indolyl) phenylmethane
- Systemic inflammation in Ab1-40-induced Alzheimer's disease model: New translational opportunities
- Biomarkers of Alzheimer's Disease Associated with Programmed Cell Death Reveal Four Repurposed Drugs
- Innate immune activation in neurodegenerative diseases
- Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort
- The proteomic landscape of microglia in health and disease
- Neurotoxic Microglial Activation via IFNγ-Induced Nrf2 Reduction Exacerbating Alzheimer's Disease
- D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease
- Proteomic Profiling of Samples Derived from a Murine Model Following Cryptococcus neoformans Infection
- The vascular contribution of apolipoprotein E to Alzheimer's disease
- A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function
- Autophagy preferentially degrades non-fibrillar polyQ aggregates
- Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial
- Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer's disease seed-dependent formation of tau aggregates
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer's disease and related dementias
- Disease and brain region specific immune response profiles in neurodegenerative diseases with pure and mixed protein pathologies
- Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
- In vivo PET classification of tau pathologies in patients with frontotemporal dementia
- Context-specific stress causes compartmentalized SARM1 activation and local degeneration in cortical neurons
- PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting
- Label free quantitative proteomic profiling of serum samples of intellectually disabled young patients revealed dysregulation of complement coagulation and cholesterol cascade systems
- Biomarkers of Neurodegeneration and Alzheimer's Disease Neuropathology in Adolescents and Young Adults with Youth-Onset Type 1 or Type 2 Diabetes: A Proof-of-Concept Study
- Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology
- Extracellular vesicles in heart failure
- Brain hypothyroidism silences the immune response of microglia in Alzheimer's disease animal model
- Parvalbumin interneuron cell-to-network plasticity: mechanisms and therapeutic avenues
- NLRP3 inflammasome signalling in Alzheimer's disease
Evidence Blueprint
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology
- Next-generation proteomics technologies in Alzheimer's disease: from clinical research to routine diagnostics
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Genomic stress and impaired DNA repair in Alzheimer disease
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases
- Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework
- Phosphorylation-state dependent intraneuronal sorting of Aβ differentially impairs autophagy and the endo-lysosomal system
- Novel aspects of the phosphorylation and structure of pathological tau: implications for tauopathy biomarkers
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology
- Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer's disease mouse model, as revealed by spatial transcriptomics
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Spatial Neurolipidomics at the Single Amyloid-β Plaque Level in Postmortem Human Alzheimer's Disease Brain
- Integration of Microfluidic Devices with Microelectrode Arrays to Functionally Assay Amyloid-β-Induced Synaptotoxicity
- Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change
- Navigating the Dementia Landscape: Biomarkers and Emerging Therapies
- Towards cascading genetic risk in Alzheimer's disease
- Mass Spectrometry Reveals that Oxysterols are Secreted from Non-Alcoholic Fatty Liver Disease Induced Organoids
- Personalized whole-brain neural mass models reveal combined Ab and tau hyperexcitable influences in Alzheimer's disease
- p-tau Ser356 is associated with Alzheimer's disease pathology and is lowered in brain slice cultures using the NUAK inhibitor WZ4003
- Proteomic analysis of the human hippocampus identifies neuronal pentraxin 1 (NPTX1) as synapto-axonal target in late-stage Parkinson's disease
- Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis
- CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection
- Induced pluripotent stem cell models as a tool to investigate and test fluid biomarkers in Alzheimer's disease and frontotemporal dementia
- CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease
- Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease
- CSF metabolites associated with biomarkers of Alzheimer's disease pathology
- Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest
- Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease
- Remodelling of the cardiac extracellular matrix proteome during chronological and pathological ageing
- Proteomics Impact on Cell Biology to Resolve Cell Structure and Function
- Neuropathology of Alzheimer's Disease
- Senile plaque-associated transactive response DNA-binding protein 43 in Alzheimer's disease: A case report spanning 16 years of memory loss
- Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease
- Human iPSC-derived retinal organoids develop robust Alzheimer's disease neuropathology
- Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease
- Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings
- Passive tau-based immunotherapy for tauopathies
- Fe65-engineered neuronal exosomes encapsulating corynoxine-B ameliorate cognition and pathology of Alzheimer's disease
- Proteomic analysis of P. gingivalis-Lipopolysaccharide induced neuroinflammation in SH-SY5Y and HMC3 cells
- Resiliency to Alzheimer's disease neuropathology can be distinguished from dementia using cortical astrogliosis imaging
- Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation
- Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation
- Evaluation of SP3 for antibody-free quantification of tau in CSF mimic and brain by mass spectrometry
- Biomarkers associated with the pathogenesis of Alzheimer's disease
- P2Y1 receptor in Alzheimer's disease
- Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
- Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics
- The Biochemistry Behind Cognitive Decline: Biomarkers of Alzheimer's Disease
- Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology
- Memantine versus Ginkgo biloba Extract: A Comparative Study on Cognitive Dysfunction Treatment in a Novel Rat Model
- Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity
- Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer's disease, restores synapse integrity and memory in a disease mouse model
- TDP-43 and Alzheimer's Disease Pathology in the Brain of a Harbor Porpoise Exposed to the Cyanobacterial Toxin BMAA
- 14-3-3 [Formula: see text]-reported early synaptic injury in Alzheimer's disease is independently mediated by sTREM2
- Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer's Disease
- A Systematic Review of the Effects of Capsaicin on Alzheimer's Disease
- Establishment of a high-content imaging assay for tau aggregation in hiPSC-derived neurons differentiated from two protocols to routinely evaluate compounds and genetic perturbations
- Thermal evaporation as sample preparation for silver-assisted laser desorption/ionization mass spectrometry imaging of cholesterol in amyloid tissues
- Pathology of neurodegenerative disease for the general neurologist
- Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy
- Mass spectrometry in cerebrospinal fluid uncovers association of glycolysis biomarkers with Alzheimer's disease in a large clinical sample